Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q3 2020 · 10-Q
Revenue$2.40M$2.40M+1.0% vs Q3 2019 Net Income-$1.01M-$1.01MN/M vs Q3 2019 EPS Diluted-$0.02-$0.02N/M vs Q3 2019 Gross Profit$47,196−87.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$224,388N/M Free Cash Flowderived-$483,817N/M Margins · derivedGross margin2.0%−13.7 pt vs Q3 2019
Operating margin-39.7%−12.5 pt vs Q3 2019
Net margin-42.1%−12.6 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 13, 2020 · 44 d after period end